Table 3. NOX1 protein expression in human malignant and benign tissue.
Organ | Pathologic diagnosis | Unstained, unscored 0+ (No. [%]) | Low expressers 1+ (No. [%]) | High expressers 2+, 3+ (No. [%]) | P value1 (statistical significance) | % cells positive | |||
---|---|---|---|---|---|---|---|---|---|
0‒9% | 10‒24% | 25‒49% | ≥50% | ||||||
Colon | Colon carcinoma | 43 [29] | 52 [36] | 51 [35] | 0.0 (***p) | 29 | 10 | 12 | 49 |
Colon adenoma | 2 [6] | 14 [44] | 16 [50] | 0.0004 (***p) | 6 | 3 | 0 | 91 | |
Colon polyp | 1 [8] | 8 [67] | 3 [25] | 0.0314 (*p) | 8 | 0 | 17 | 75 | |
Inflammatory lesions | 0 [0] | 11 [85] | 2 [15] | 0.0853 (n.s.) | 0 | 8 | 8 | 85 | |
Normal colon | 0 [0] | 18 [100] | 0 [0] | 0 | 0 | 44 | 56 | ||
Small intestine | Small intestine carcinoma | 56 [51] | 37 [34] | 17 [15] | 0.0137 (*p) | 51 | 20 | 12 | 17 |
Small intestine inflammatory lesions | 30 [88] | 3 [9] | 1 [3] | 0.1562 (n.s.) | 88 | 0 | 6 | 6 | |
Normal small intestine | 25 [76] | 8 [24] | 0 [0] | 76 | 0 | 12 | 12 | ||
Prostate | Prostate carcinoma | 180 [98] | 0 [0] | 3 [2] | 0.7328 (n.s.) | 98 | 0 | 1 | 1 |
Normal prostate | 7 [100] | 0 [0] | 0 [0] | 100 | 0 | 0 | 0 | ||
Ovary | Ovarian carcinoma | 155 [95] | 6 [4] | 2 [1] | 0.9497 (n.s.) | 95 | 0 | 2 | 2 |
Normal ovarian tissue adjacent to cancer | 2 [100] | 0 [0] | 0 [0] | 100 | 0 | 0 | 0 | ||
Lung | Lung carcinoma | 143 [99] | 1 [1] | 0 [0] | 0.5972 (n.s.) | 99 | 0 | 1 | 0 |
Normal lung | 40 [100] | 0 [0] | 0 [0] | 100 | 0 | 0 | 0 | ||
Stomach | Gastric carcinoma | 14 [82] | 1 [6] | 2 [12] | 0.0735 (n.s.) | 82 | 0 | 0 | 18 |
Gastric inflammatory lesions | 38 [90] | 4 [10] | 0 [0] | 90 | 7 | 0 | 2 | ||
Breast | Breast carcinoma | 162 [80] | 33 [16] | 8 [4] | 0.8514 (n.s.) | 80 | 0 | 0 | 19 |
Normal breast | 6 [86] | 1 [14] | 0 [0] | 86 | 0 | 0 | 14 |
Tissues were scored as unstained (0+), low NOX1 expressers (1+), or high NOX1 expressers (2+, 3+). Percentage of tissues per score is shown in brackets. n.s., not statistically significant.
1The Chi-square statistical test was used to determine significant differences between the proportions of low (1+) and high expressers (2+, 3+) between malignant tissue and matched or adjacent normal tissue.